A procedure for removing high titer antibodies by extracorporeal protein-A-sepharose adsorption in hemophilia: substitution therapy and surgery in a patient with hemophilia B and antibodies.

No abstract is available for this paper.

• Publication year

  1981

• Venue

  Blood

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers
  DOI 10.1182/blood.v58.1.38.38PMID 7236891
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• On an inherited autosomal hemorrhagic diathesis with antihemophilic globulin (AHG) deficiency and prolonged bleeding time.

  2009cited by this paper
• Immunosuppressive treatment in haemophiliacs with inhibitors to factor VIII and factor IX.

  2009cited by this paper
• Haemophilia in Sweden. I. Coagulation studies.

  2009cited by this paper
• Activated F IX concentrate (FEIBA) used in the treatment of haemophilic patients with antibody to F VIII.

  2009cited by this paper
• Clinical experience with a Swedish factor IX concentrate.

  2009cited by this paper
• Quantitation of J chain in human biological fluids by a simple immunochemical procedure.

  2009cited by this paper
• Immunologic studies in haemophilia A.

  2009cited by this paper
• Prenatal diagnosis of hemophilia B by an immunoradiometric assay of factor IX.

  1980cited by this paper
• Decreased ionized calcium during therapeutic plasma exchange pheresis and platelet pheresis.

  1980cited by this paper
• Coagulation Abnormalities Produced by Plasma Exchange on the Cell Separator with Special Reference to Fibrinogen and Platelet Levels

  1979cited by this paper
• Studies on the Thrombogenic Activities in Two Prothrombin Complex Concentrates

  1979cited by this paper
• The hemostatic imbalance of plasma-exchange transfusion.

  1979cited by this paper
• Multiple dental extractions with a new prothrombin complex concentrate in two patients with factor VIII inhibitors.

  1979cited by this paper
• Prothrombin complex concentrates. Use in treatment of hemophiliacs with factor VIII inhibitors.

  1978cited by this paper
• Ex vivo removal of serum igg in a patient with colon carcinoma.Some biochemical, immunological and histological observations

  1978cited by this paper
• Prothrombin complex concentrates.

  1978cited by this paper
• Serial plasmapheresis in a haemophiliac with antibodies to FVIII.

  1977cited by this paper
• Factor VIII inhibitor by-passing activity (FEIBA) in the management of patients with factor VIII inhibitors.

  1977cited by this paper
• Treatment of Anti-Factor VIII Antibodies

  1977cited by this paper
• Factor VIII inhibitor bypassing activity.

  1976cited by this paper
• Letter: Factor-VIII inhibitor bypassing activity.

  1976cited by this paper
• Various Prothrombin Complex Concentrates and their Effect on Coagulation and Fibrinolysis In Vivo

  1976cited by this paper
• Potentially Thrombogenic Materials in Factor IX Concentrates

  1975cited by this paper
• Heparin cofactor activity measured with an amidolytic method.

  1975cited by this paper
• Treatment of life-threatening hemorrhage due to acquired factor VIII inhibitor.

  1975cited by this paper
• Complement Components in Normal Serum and Plasma Quantitated by Electroimmunoassay

  1975cited by this paper
• Potentially thrombogenic materials in factor IX concentrates.

  1975cited by this paper
• A More Uniform Measurement of Factor VIII Inhibitors

  1975cited by this paper
• Management of Patients with Factor VIII or IX Inhibitors

  1974cited by this paper
• Thrombogenic materials in prothrombin complex concentrates.

  1974cited by this paper
• The Treatment of Patients who have Factor‐VIII Antibodies

  1973cited by this paper
• Suppression of factor IX antibody in hemophilia B by factor IX and cyclophosphamide.

  1973cited by this paper
• Successful management of a subdural hematoma in a hemophiliac with an anti-factor VIII antibody.

  1973cited by this paper
• Antithrombin III in a clinical material

  1973cited by this paper
• Parallel Determinations of FDP and Fibrin Monomers with Various Methods

  1972cited by this paper
• Ethanol gelation and fibrin monomers in plasma.

  1971cited by this paper
• Differences in anti-protein A activity among IgG subgroups.

  1969cited by this paper
• Acquired circulating anticoagulants in hemophilia A.

  1969cited by this paper
• Separation and Estimation of Split “Products” of Fibrinogen and Fibrin in Human Serum

  1967cited by this paper
• Clinical use of human prothrombin complexes.

  1965cited by this paper

• Extracorporeal affinity systems and immunoadsorption therapies

  2022cites this paper
• Immunoadsorption for the Treatment of Acquired Hemophilia: New Observational Data, Systematic Review, and Meta-Analysis.

  2021cites this paper
• Comparative Population Pharmacokinetics of Darunavir in SARS-CoV-2 Patients vs. HIV Patients: The Role of Interleukin-6

  2020cites this paper
• Clinical Care of Bone Health in Patients on the Immune Tolerance Induction’s Protocols With an Immunosuppressive Agent for Inhibitor Eradication in Hemophilia

  2020cites this paper
• Therapeutic apheresis

  2016cites this paper
• Immune tolerance induction in hemophilia

  2015cites this paper
• Immunosuppressive agents in the treatment of inhibitors in congenital haemophilia A and B – a systematic literature review

  2014cites this paper
• Advances in bypassing agent therapy for hemophilia patients with inhibitors to close care gaps and improve outcomes

  2011influential citation
• A new drug form of blood coagulation factor IX: red blood cell-entrapped factor IX.

  2010cites this paper
• Suppression of secondary antibody response by intravenous immunoglobulin and development of tolerance in a patient with haemophilia B and antibodies.

  2009cites this paper
• Extracorporeal Immunoadsorption for the Treatment of Coagulation Inhibitors

  2009cites this paper
• Suppression of secondary antibody response by intravenous immunoglobulin in a patient with haemophilia b and antibodies.

  2009cites this paper
• Characterisation of the tolerant state in a patient with haemophilia B after removal of high-titre factor IX antibodies.

  2009cites this paper
• Pregnancy and parturition in a patient with severe Glanzmann's thrombasthenia.

  2009cites this paper
• Long-term high dose factor VIII treatment of 3 haemophiliacs with factor VIII inhibitor.

  2009cites this paper
• Adaptability of protein A-immunoadsorption allows temporary reduction of anti-VIII antibodies and realisation of high-risk haemorrhagic surgery.

  2007cites this paper
• Managing acute bleeds in the patient with haemophilia and inhibitors: options, efficacy and safety.

  2005cites this paper
• Managing acute bleeds in the patient with haemophilia and inhibitors: options, efficacy and safety

  2005cites this paper
• The Idiotypic Characteristics of Human Antibodies to Factor

  2005cites this paper
• Immunoadsorption of factor VIII inhibitors.

  2004cites this paper
• Ablation of hemophilic FVIII inhibitors with FVIII priming, cyclophosphamide immune suppression, and rapid tapering of FVIII immune tolerance

  2004cites this paper
• Immunoadsorption may provide a cost‐effective approach to management of patients with inhibitors to FVIII

  2003cites this paper
• Haemophilia: treatment options

  2003cites this paper
• Haemophilia: treatment options

  2003cites this paper
• Erworbene Hämophilie infolge Antikörperbildung gegen Faktor VIII

  2003cites this paper
• Factor concentrate usage in persons with hemophilia in New York State

  2003cites this paper
• Correcting Immune Imbalance: The Use of Prosorba Column Treatment for Immune Disorders

  2003cites this paper
• Extracorporeal adsorption of anti-Factor VIII allo-antibodies on randomly functionalized polystyrene resins

  2003cites this paper
• Treatment of the Bleeding Inhibitor Patient

  2003cites this paper
• Use of Protein‐A column and porcine factor VIII

  2002cites this paper
• Use of a modified zirconia support in the separation of immunoproteins.

  2002cites this paper
• Polystyrene derivatives as candidates for extracorporeal adsorption of Factor VIII antibodies in the management of haemophiliac patients

  2002cites this paper
• Role of apolipoprotein e (apoe) polymorphism on left cardiac failure in homozygous β thalassaemic patients

  2001cites this paper
• Central nervous system relapse of acute promyelocytic leukaemia in a patient with cerebral haemorrhage at diagnosis

  2001cites this paper
• Thrombopoietin concentration after orthotopic liver transplantation

  2001cites this paper
• Reply to mehta and burroughs

  2001cites this paper
• Protein A sepharose immunoadsorption: immunological and haemostatic effects in two cases of acquired haemophilia

  2001cites this paper
• Treatment of acquired factor viii autoantibodies by immunoadsorption

  2001cites this paper
• Immune tolerance induction in haemophilia A patients with high‐responding inhibitors to factor VIII: experience at a single institution

  2001cites this paper
• [Acquired factor VIIIc inhibitors. Two cases and a review of the literature].

  2001cites this paper
• Treatment of patients with factor viii autoantibodies by staphylococcal protein a‐based immunoadsorption and immunosuppression

  2001cites this paper
• Rationale for the use of high dose rFVIIa in a high‐titre inhibitor patient with haemophilia B during major orthopaedic procedures

  2001cites this paper
• Plasma cell subtypes in bone marrow biopsies from patients without plasma cell dyscrasia

  2001cites this paper
• Immunoadsorption, current status and future developments

  2000cites this paper
• Removal of xenoreactive antibodies by protein‐A immunoadsorption: experience in 22 patients

  2000cites this paper
• Protein A-immobilized microporous polyhydroxyethylmethacrylate affinity membranes for selective sorption of human-immunoglobulin-G from human plasma

  2000cites this paper
• Immune tolerance induction in the treatment of paediatric haemophilia A patients with factor VIII inhibitors

  2000cites this paper
• Protein A immobilization and HIgG adsorption onto porous/nonporous and swellable HEMA-incorporated polyEGDMA microspheres

  2000cites this paper
• Tolerance induction using the Malmö treatment model 1982–1995

  1999cites this paper
• Protein A tangential flow affinity membrane cartridge for extracorporeal immunoadsorption therapy.

  1999cites this paper
• Induction of immune tolerance with recombinant factor VIII in haemophilia A patients with inhibitors

  1999cites this paper
• Extracorporeal Immunoadsorption for the Treatment of Haemophilic Patients with Inhibitors to Factor VIII or IX

  1999cites this paper
• Treatment of Patients with Factor VIII and Factor IX Inhibitors with Special Focus on the Use of Recombinant Factor VIIa

  1999cites this paper
• Response of patients with IgM and IgA‐associated peripheral polyneuropathies to “off‐line” immunoadsorption treatment using the Prosorba® protein A column

  1999cites this paper
• Reduction of Acquired High Titer Factor VIII Antibodies by Extracorporeal Antibody-based Immunoadsorption without Additional Immunosuppressive Therapy

  1998cites this paper
• Immunoadsorption for removal of inhibitors: update on treatments in Malmö–Lund between 1980 and 1995

  1998cites this paper
• Ig-Therasorb immunoadsorption for selective removal of human immunoglobulins in diseases associated with pathogenic antibodies of all classes and IgG subclasses, immune complexes, and fragments of immunoglobulins.

  1998cites this paper
• The future of selective apheresis in FAP.

  1998cites this paper
• Prednisone and low‐dose activated prothrombin complex concentrates for FVIII inhibitor in nonhaemophilic patients

  1998cites this paper
• Haemophilia.

  1997cites this paper
• Multicenter Retrospective Study on the Utilization of FEIBA in France in Patients with Factor VIII and Factor IX Inhibitors

  1997cites this paper
• Current Practice in the Treatment of Haemophilia.

  1997cites this paper
• Therapy of coagulation factor VIII autoantibodies with long-term extracorporeal protein A adsorption and immunosuppression.

  1997cites this paper
• Affinity of human anti‐factor VIII antibodies for functional polystyrene supports

  1996cites this paper
• Protein a Carrying Monosize PMMA Microbeads for the Removal of HlgG from Human Plasma

  1996cites this paper
• [Plasma- and lymphapheresis in autoimmune diseases].

  1996cites this paper
• Inhibitors in congenital haemophilia.

  1996cites this paper
• Anomalies préopératoires de l’hémostase

  1996cites this paper
• Acquired inhibitors.

  1996cites this paper
• Hemostasis: a practical review of conservative and operative care.

  1996cites this paper
• Apheresis. New opportunities.

  1996cites this paper
• Inhibitors of factor VIII and IX

  1995cites this paper
• Protein A immobilized polyhydroxyethylmethacrylate beads for affinity sorption of human immunoglobulin G.

  1995cites this paper
• Elimination of Acquired Factor VIII Antibodies by Extracorporal Antibody-based Immunoadsorption (Ig-Therasorb®)

  1995cites this paper
• Hemophilia A.

  1994cites this paper
• Factor VIII inhibitor treatment. Immune tolerance.

  1994cites this paper
• Tyrosyl sulfamide derivatives as ligands for affinity adsorption of anti FVIII antibodies.

  1994cites this paper
• Progress in the Understanding of Factor VIII Inhibitors

  1994cites this paper
• Treatment of autoimmune disease by immunomodulation through extracorporeal elimination and intravenous immunoglobulin.

  1994cites this paper
• Plasmapheresis as a therapy in specific forms of acute renal failure.

  1994cites this paper
• Treatment of patients with refractory rheumatoid arthritis with extracorporeal protein A immunoadsorption columns: a pilot trial.

  1994cites this paper
• Removal of beta 2-microglobulin using grafted affinity adsorbents as therapeutic approach for the treatment of hemodialysis patients.

  1994cites this paper
• Preformed antibody and complement rebound after plasma exchange: analysis of immunoglobulin isotypes and effect of splenectomy.

  1994cites this paper
• "Circulating anticoagulants: a study of 40 cases and a review of the literature. 1961.": an update.

  1993cites this paper
• Some complications of the therapy of hemorrhagic disorders.

  1993cites this paper
• Therapeutic Plasma Adsorption. A Review

  1993cites this paper
• Evaluation of a new polyacrolein microsphere (acrobead) protein A column: an in vitro study using the blood of patients with immune thrombocytopenia or malignancies

  1992cites this paper
• Treatment of congenital and acquired hemophilia patients by extracorporeal removal of antibodies to coagulation factors: a review of US clinical studies 1987-1990. Hemophilia Study Group.

  1992cites this paper
• Management of hemophilia patients with inhibitors.

  1992cites this paper
• Biologically modified PHEMA beads for hemoperfusion: preliminary studies.

  1992cites this paper
• An IgG inhibitor against coagulation factor XIII: resolution of bleeding after plasma immunoadsorption with staphylococcal protein A.

  1992cites this paper
• Successful treatment of acquired factor VIII antibody by extracorporeal immunoadsorption.

  1991cites this paper
• The development of selective plasmapheresis as a means for specific therapeutic intervention

  1991cites this paper
• Treatment of rapidly progressive glomerulonephritis by extracorporeal immunoadsorption, prednisolone and cyclophosphamide.

  1991cites this paper
• Kinetic Aspects of the Removal of IgG and Inhibitors in Hemophiliacs Using Protein A Immunoadsorption 1

  1991cites this paper
• Biocompatibility of extracorporeal immunoadsorption systems.

  1990cites this paper
• Elective surgery in a haemophilic patient with high titre inhibitors: use of extracorporeal protein A immunoabsorption.

  1990cites this paper
• Extracorporeal removal of anti-HLA antibodies in transplant candidates.

  1990cites this paper
• Model of Removal of Immunoglobulins from Plasma by Extracorporeal Immunoadsorption with Sepharose-Protein A

  1990influential citation
• Humoral immune response following extracorporeal immunoadsorption therapy of patients with hypercholesterolemia

  1990cites this paper